Altan Pharma Announces Licensing Agreement for Generic of Antifungal Agent Caspofungin
Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that it has signed a licensing agreement to commercialise a generic version of caspofungin. The agreement covers the territories of Germany, France, Italy, Spain, the United Kingdom, Belgium, Portugal, Poland and Latin America.
Chairman and Chief Executive Officer of Altan Pharma, Guillermo Herrera stated: “Licensing the rights to generic caspofungin reflects a significant step forward for Altan as we continue to build a strong portfolio of injectable drugs which we can bring to the European and other markets. Altan are committed to building a deep and diverse pipeline through ongoing internal development, in-licensing and further acquisitions.”
According to IMS, the market for caspofungin in the European countries covered by the agreement was approximately €260 million 2015.
About Caspofungin Solution for Infusion
Caspofungin is an antifungal medicine indicated for the:
- Treatment of invasive candidiasis in adult or pediatric patients;
- Treatment of invasive aspergillosis in adult or pediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or Iitraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;
- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus ) in febrile, neutropenic adult or pediatric patients.
Please see the package insert for indications, complete side effect profile and prescribing information.
About Altan Pharma Ltd.
Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, manufactures and commercialises injectable drugs for the hospital and other provider segments. Altan has an international distribution network covering many European, Latin American and Asian markets. The company is highly focused on building its pipeline of injectable drugs and expanding its commercial presence to new markets through both organic and inorganic means.
For more information visit www.altanpharma.com
Altan Media Relations
Tel: +353 (1) 908 1280
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
TX-VIKING-ACQUISITION22.6.2018 13:11 | pressemeddelelse
Announcement by Viking Corp on Tecnotree
TX-HEARTSCIENCES22.6.2018 13:02 | pressemeddelelse
HeartSciences Named “Start-Up to Watch”
CNIM22.6.2018 11:41 | pressemeddelelse
High-Performance Solutions and Complete Protection for Critical Installations: the Latest Innovations from CNIM and Its Bertin Subsidiary to Be Unveiled at WNE 2018
MOODY’S-ANALYTICS22.6.2018 09:02 | pressemeddelelse
Wealthify Selects Moody’s Analytics Modeling Technology to Support Its Online Investment Proposition
LOXAM-GROUP/NO.VE.22.6.2018 09:02 | pressemeddelelse
Loxam Announces the Acquisition of Italian Powered Access Rental Specialist Nove
CA-OPENGATE-CAPITAL22.6.2018 08:02 | pressemeddelelse
OpenGate Capital Completes Sale of NorPaper Group to Gemayel Freres & Chaoui Industriel Group
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum